SpringWorks Therapeutics Overview
- Year Founded
-
2017
- Status
-
Public
- Employees
-
305
- Stock Symbol
-
SWTX
- Investments
-
1
- Share Price
-
$34.01
- (As of Friday Closing)
SpringWorks Therapeutics General Information
Description
SpringWorks Therapeutics Inc is a clinical stage biopharmaceutical company applying a precision medicine approach to acquiring, developing and commercializing life-changing medicines for underserved patient populations suffering from devastating rare diseases and cancer. The company has a differentiated portfolio of small molecule targeted oncology product candidates and is advancing two potentially registrational clinical trials in rare tumor types, as well as several other programs addressing highly prevalent, genetically defined cancers.
Contact Information
Website
www.springworkstx.comCorporate Office
- 100 Washington Boulevard
- Stamford, CT 06902
- United States
Corporate Office
- 100 Washington Boulevard
- Stamford, CT 06902
- United States
SpringWorks Therapeutics Stock Performance
As of 08-Nov-2024, SpringWorks Therapeutics’s stock price is $34.01. Its current market cap is $2.52B with 74.3M shares.
(As of Friday Closing)
Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
---|---|---|---|---|---|---|
$34.01 | $33.09 | $18.00 - $53.92 | $2.52B | 74.3M | 864K | -$4.44 |
SpringWorks Therapeutics Financials Summary
As of 30-Jun-2024, SpringWorks Therapeutics has a trailing 12-month revenue of $86.2M.
In Thousands, USD |
TTM 30-Jun-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 |
---|---|---|---|---|
EV | 2,360,815 | 2,267,080 | 976,353 | 2,626,178 |
Revenue | 86,186 | 5,447 | 0 | 0 |
EBITDA | (324,072) | (346,384) | (282,799) | (173,966) |
Net Income | (301,063) | (325,104) | (277,417) | (173,910) |
Total Assets | 617,331 | 725,788 | 630,242 | 452,494 |
Total Debt | 7,059 | 7,057 | 5,251 | 1,291 |
SpringWorks Therapeutics Valuation & Funding
Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
---|
SpringWorks Therapeutics Comparisons
Industry
Financing
Details
SpringWorks Therapeutics Competitors (98)
One of SpringWorks Therapeutics’s 98 competitors is Travere Therapeutics, a Formerly VC-backed company based in San Diego, CA.
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
Travere Therapeutics | Formerly VC-backed | San Diego, CA | ||||
Lexeo Therapeutics | Formerly VC-backed | New York, NY | ||||
NexImmune | Formerly VC-backed | Gaithersburg, MD | ||||
Galectin Therapeutics | Corporation | Norcross, GA | ||||
Nimbus Therapeutics | Venture Capital-Backed | Boston, MA |
SpringWorks Therapeutics Patents
SpringWorks Therapeutics Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
US-12029711-B1 | Dosage forms of mirdametinib | Active | 16-Mar-2023 | ||
US-20240307326-A1 | Dosage forms of mirdametinib | Pending | 16-Mar-2023 | ||
US-20240307327-A1 | Dosage forms of mirdametinib | Pending | 16-Mar-2023 | ||
US-20240358661-A1 | Dosage forms of mirdametinib | Pending | 16-Mar-2023 | ||
US-20240122881-A1 | Combination for use in treating cancers | Pending | 14-Oct-2022 | A61K31/165 |
SpringWorks Therapeutics Signals
SpringWorks Therapeutics Investors
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|
SpringWorks Therapeutics Investments (1)
SpringWorks Therapeutics’s most recent deal was a Joint Venture with MapKure. The deal was made on 18-Jun-2019.
Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
---|---|---|---|---|---|
MapKure | 18-Jun-2019 | Joint Venture | Drug Discovery |
SpringWorks Therapeutics ESG
Risk Overview
Risk Rating
Updated October, 15, 2024
36.1 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 15,035
Rank
Percentile
Pharmaceuticals
Industry
of 847
Rank
Percentile
Pharmaceuticals
Subindustry
of 423
Rank
Percentile
SpringWorks Therapeutics FAQs
-
When was SpringWorks Therapeutics founded?
SpringWorks Therapeutics was founded in 2017.
-
Where is SpringWorks Therapeutics headquartered?
SpringWorks Therapeutics is headquartered in Stamford, CT.
-
What is the size of SpringWorks Therapeutics?
SpringWorks Therapeutics has 305 total employees.
-
What industry is SpringWorks Therapeutics in?
SpringWorks Therapeutics’s primary industry is Drug Discovery.
-
Is SpringWorks Therapeutics a private or public company?
SpringWorks Therapeutics is a Public company.
-
What is SpringWorks Therapeutics’s stock symbol?
The ticker symbol for SpringWorks Therapeutics is SWTX.
-
What is the current stock price of SpringWorks Therapeutics?
As of 08-Nov-2024 the stock price of SpringWorks Therapeutics is $34.01.
-
What is the current market cap of SpringWorks Therapeutics?
The current market capitalization of SpringWorks Therapeutics is $2.52B.
-
What is SpringWorks Therapeutics’s current revenue?
The trailing twelve month revenue for SpringWorks Therapeutics is $86.2M.
-
Who are SpringWorks Therapeutics’s competitors?
Travere Therapeutics, Lexeo Therapeutics, NexImmune, Galectin Therapeutics, and Nimbus Therapeutics are some of the 98 competitors of SpringWorks Therapeutics.
-
What is SpringWorks Therapeutics’s annual earnings per share (EPS)?
SpringWorks Therapeutics’s EPS for 12 months was -$4.44.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »